Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer

NCT03316599 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: Gemcitabine
DRUG: Nab-paclitaxel
DRUG: Ficlatuzumab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]